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a skin deterioration (ﬂare). METHODS: Multi-centre,
cross-sectional, prospective QoL study. Information
including demographic and disease characteristics was
collected with semi-structured patient questionnaire 
and by chart abstraction. Disease-speciﬁc instruments:
PIQoL-AD (Parents Index Quality of Life—Atopic Der-
matitis; score: 0–28 points) for parents of children up to
8 years, QoLIAD (Quality of Life Index Atopic Dermati-
tis; score: 0–25 points) for patients over 16 years. CDLQI
(Children Dermatology Life Quality Index; score: 0–30
points) was used for patients aged 9–16 years. Higher
scores indicate greater impairment of QoL. EQ-5D was
used to assess preferences (utilities) of patients over 16
years. RESULTS: A total of 193 patients enrolled at 
16 centers (10 ofﬁce-based dermatologists, 4 ofﬁce-based
paediatricians, 1 outpatient unit of a dermatology hospi-
tal, 1 patient organization) sent back the questionnaires.
Mean age (range): 23 years (1–71 years), 63% female.
27% of the patients had a mild, 38% a moderate and
35% a severe course of disease. Median duration of
current ﬂare: 12 days. Mean utility value during a ﬂare
was 0.69 (SD 0.26). After ﬂare mean utility value rose up
to 0.82 (SD 0.17). Atopic dermatitis-speciﬁc instruments
(PIQoL-AD/QoLIAD) showed reductions in QoL during
a ﬂare in comparison to the period after ﬂare: 10.2 (SD
7.3) vs. 6.4 (SD 6.1)/11.4 (SD 7.2) vs. 7.5 (SD 6.6).
Patients aged 9–16 years (CDLQI) reported comparable
impairment of QoL during (9.8, SD 3.8) and after a ﬂare
(9.6, SD 3.9). CONCLUSIONS: Patients’ and parents’
QoL is reduced considerably during a ﬂare of atopic der-
matitis. Health status (utility value) of patients during a
ﬂare is comparable to health status of patients with other
chronic diseases like e.g. diabetes type II.
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COSTEFFECTIVENESS OF ALEFACEPT IN
PATIENTS WITH MODERATE TO SEVERE
PSORIASIS
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University of Tromso,Tromso, Norway
OBJECTIVES: To estimate the incremental costs and
incremental health effects of replacing methotrexate
(MTX) by alefacept (Amevive) in patients with moderate
to severe psoriasis (PASI-score 10+). METHODS: A total
of 36 patients with moderate to severe psoriasis were
interviewed about quality of life and treatment costs.
Disease severity was measured by PASI-score (Psoriasis
Area and Severity Index) while quality of life was mea-
sured by a multiattribute utility instrument (15D) and a
disease speciﬁc instrument (DLQI-N). Cost of psoriasis
therapy during the past three months was estimated on
the basis of patients’ utilization reports and unit costs. A
Markov model with 4 health states based on PASI-score
(0, 1–9, 10–19, 20+), 12 weeks cycles and 2 years time
horizon was developed. Transition probabilities were
derived from published clinical trials (MTX and ale-
facept) and websites (alefacept), but no head-to-head
trials were available. The beneﬁt from psoriasis therapy
was expressed in terms of QALYs, and sensitivity analy-
ses were used to explore the robustness of the results.
RESULTS: Quality of life was estimated at 0.94, 0.91,
0.88, and 0.77 in the four PASI-groups. Average 3 months
psoriasis treatment costs were $384, $509, and $960 for
patients with PASI-score 1–9, 10–19, 20+ respectively. In
the base case, alefacept has higher costs and lower health
beneﬁt, and this result was fairly robust to a wide range
of changes in the model parameters. Only when all para-
meters values were assumed as favourable as conceivable
for alefacept and as unfavourable as conceivable for
MTX, the cost per QALY came down to $76,400. CON-
CLUSION: Alefacept seems to represent greater costs and
smaller health beneﬁts than MTX in patients with mod-
erate to severe psoriasis. There is an urgent need to
conﬁrm these results in head-to-head trials of MTX and
alefacept.
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OBJECTIVE: To describe quality of life (QoL) and
patients’ preferences in psoriasis patients with current
skin deterioration and 6 weeks later after subsequent
therapy. METHODS: Prospective, multi-center, cross-sec-
tional, quality of life study combined with a cost-of-illness
study. Patients (over 17 years; with moderate and severe
course of disease) were enrolled consecutively by 12
ofﬁce-based dermatologists and by 5 outpatient depart-
ments in dermatology hospitals. Instruments: DLQI (Der-
matology Life Quality Index; sum score: 0–30 points; 0
= no reductions in QoL), EQ-5D, semi-structured patient
questionnaire. RESULTS: A total of 227 patients were
enrolled. 197 sent back the quality of life questionnaire
part A (within current skin deterioration) and 151
patients part B (6 weeks later). Mean age were 47 years,
55% were male. Mean DLQI score during the current
skin deterioration accounted 9.3 (SD 6.8) and varied from
0 to 27 points; 6 weeks later DLQI score decreased to 6.8
(SD 5.2). The mean utility value was 0.79 (SD 0.18) at
enrollment due to current skin deterioration and showed
the same ﬁgure 6 weeks later (0.80, SD 0.17). DLQI score
indicated greater reductions of QoL due to a current skin
deterioration in patients with severe course of psoriasis
(10.4, SD 7.1) than in patients with moderate form of
psoriasis (8.4, SD 6.4). Mean DLQI score decreased from
9.1 (SD 6.8) to 7.0 (SD 5.7) in patients with topical treat-
ment and/or phototherapy within 6 weeks. In patients
treated with systemic medication additionally, mean
DLQI score fell from 8.3 (SD 5.6) to 5.7 (SD 4.0). CON-
CLUSIONS: The considerable reduction in QoL due to a
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current skin deterioration in patients suffering from 
moderate or severe psoriasis vulgaris underline the neces-
sity for innovative, long-lasting therapies with few 
side-effects.
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DURATION OF PSORIASIS AND QUALITY OF
LIFE
Taïeb C, Marionneau N, Myon E
Pharmaco Economics & Quality of Life Department,
Boulogne Billancourt, France
Quality of life questionnaires enable patients to express
their personal evaluation of the consequences of their
condition and/or treatment. Psoriasis has a heavy impact
on the physical and mental well-being of the patient.
OBJECTIVE: To evaluate the impact of the duration of
psoriasis on the quality of life of patients. METHOD:
Within the context of the SPOT study, 668 patients
(newly diagnosed patients: n = 319, Patients followed for
longer than 5 years: n = 347) responded to a quality of
life questionnaire consisting of a generic scale (SF-12) and
a speciﬁc scale (PDI–Psoriasis Disability Index). The com-
pleted questionnaires were returned in prepaid envelopes.
RESULTS: The socio-demographic proﬁle of the patients
in the two groups did not present any statistically signif-
icant difference (place of residence, lifestyle). The mean
age was respectively 42.9 years for newly diagnosed
patients versus 48.1 years for patients who had been fol-
lowed for longer than 5 years. The PDI score was 10.7%
(SD = 11.7) for newly diagnosed patients and 15.7% (SD
= 13.5) for patients that had been followed for longer
than 5 years (p < 0.0001). With regard to the SF-12, the
results were organised in 2 scores: mental (MCS-12) and
physical (PCS-12). The scores for newly diagnosed
patients were: PCS-12 = 52.4 (SD = 7.1) & MCS-12 =
42.8 (SD = 10.5) the scores for the Patients followed for
longer than 5 years were: PCS-12 = 50.6 (SD = 8.0) &
MCS-12 = 41.0 (SD = 10.7). The differences observed in
the two dimensions, physical and mental, were statisti-
cally signiﬁcant (p = 0.0038 and p = 0.0281). CON-
CLUSION: These results show a quality of life’s
impairing for the population that had been followed for
longer than 5 years, a difference conﬁrmed by both the
speciﬁc and generic scales.
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PSORIASIS: IMPACT OF THE TREATMENT ON
QUALITY OF LIFE
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Psoriasis is a chronicle disease, which concerns 4.7% of
the European population. Even if it does not question the
vital prognosis, it is a very invalidating condition in daily
life because of the damage to the body image. Therefore
the patients’ quality of life improvement is one of the
medical treatment’s priority. OBJECTIVE: To assess the
impact of a medical strategy on patients’ quality of life.
METHOD: SPOT is a longitudinal, prospective observa-
tional program following 400 psoriasis patients in Spain
The Psoriasis Disability Index (Pr Finlay, 1987) and the
SF12 are evaluated, the completed questionnaires were
returned by post. RESULTS: In this ﬁrst analysis, the ﬁrst
74 patients were taken into account and analysed at inclu-
sion and 3 months after the treatment initiation. The PDI
score at inclusion is 11.88 (sd = 10). The PDI score 3
months after is 8.88 (sd = 9.48). These ﬁrst results show
evidence of an improvement of patients’ quality of life 3
months after treatments (p < 0.02). Concerning the SF-
12, the results consisted of two scores: mental (MCS-12)
and physical (PCS-12). At inclusion the SF12 scores were:
PCS-12 = 50 (sd = 8) & MCS-12 = 49.9 (sd = 9.8), 3
months after the scores were the following PCS-12 = 52
(sd = 7.6) & MCS-12 = 50.7 (sd:7.6). The improvement
of the quality of life in their physical health dimension is
statistically signiﬁcant (p < 0.03). CONCLUSION: Con-
cerning the PDI, the following dimensions “daily activi-
ties, leisure and social relations” are signiﬁcantly
improved (p < 0.02), which might have consequences on
patients’ daily life.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. The large number of
quality of life studies that exist conﬁrms this. OBJEC-
TIVES: To evaluate the effect of psoriasis on quality of
life of patients in Spain. METHOD: A total of 4500
anonymous questionnaires (comprised of two scales: the
Psoriasis Disability Index (PDI) plus 10 questions con-
cerning treatment and evolution of psoriasis) were sent,
via a Psoriasis Patient Support Group (AccionPsoriasis).
RESULTS: A total of 1900 questionnaires were returned
(June 2002): response rate 42%. An analysis of the ﬁrst
810 questionnaires was realised. The sex ratio Men
(M)/Women(W) was: 49/51. Mean age: 42 years. Mean
age of diagnosis: 21.8 years. The average to the total score
was 8.47 (s.d. 7.2 rank 0 to 39) i.e. 18.82 (s.d.: 17.2)
when reported to a scale of 0 to 100. Signiﬁcant differ-
ence was observed between M and W for the global 
handicap score 20.73 vs 16.95 p < 0.002. Two groups
was identiﬁed: pousée de psoriasis (84%), pas de poussée
de psorisis (12%)—no answers (4%). Psoriasis had a
greater adverse affect on patients with crise: PDI score =
20.24 (sd 17.52) than the patient without actual crise 
PDI score = 8.98 (sd 11.34). This difference was signi-
ﬁcative p < 0.00001. CONCLUSION: These results high-
light the value of appropriate and relevant psychological
